Mergers & AcquisitionsMedium•13 November 2026•
1 min read
Sanofi Acquires Vicebio and Dynavax for $3.4 Billion to Boost Vaccine Portfolio
Key Facts
1Sanofi announced the acquisition of Vicebio and Dynavax in a transaction valued at $3.4 billion.
Sanofi announced the acquisition of Vicebio and Dynavax in a transaction valued at $3.4 billion. Benzinga reported that the company entered into the agreement to strengthen its existing vaccine portfolio through the integration of new technologies and products.
This strategic move expands a core business segment for the pharmaceutical giant. SNY closed at $48.46 on November 12, 2026, with the stock recording a session high of $48.96 and a low of $48.4.